CA 125 screening for ovarian cancer measures levels of a glycoprotein produced by most epithelial ovarian cancers, but it is not recommended for routine use in asymptomatic women due to poor specificity and limited ability to detect early-stage disease.
CA 125 is a tumor antigen expressed on the surface of many ovarian cancer cells. Elevated serum levels above 35 U/mL are considered abnormal, though levels can rise in non-cancerous conditions such as endometriosis, pelvic inflammatory disease, and liver cirrhosis. This lack of specificity limits its value as a standalone screening tool.
The test is primarily used to monitor treatment response and recurrence in patients already diagnosed with ovarian cancer. For example, a patient with stage III serous adenocarcinoma may have a baseline CA 125 of 800 U/mL. After six cycles of carboplatin and paclitaxel chemotherapy, the level drops to 40 U/mL, indicating a positive response. A subsequent rise above 100 U/mL often precedes clinical evidence of relapse by several months.
CA 125 is measured via a standard blood draw. Results are reported in units per milliliter (U/mL). A value above 35 U/mL is considered elevated and prompts further investigation, including imaging and possibly biopsy.
However, the test's performance varies widely. In a study of 1,000 women without symptoms, only 2% had CA 125 levels above 35 U/mL, yet among those, only 1 in 500 had ovarian cancer. This results in a positive predictive value below 1%, meaning most elevated results are false positives.
Even in symptomatic women, CA 125 lacks sensitivity for early-stage disease. A 2016 analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) found that CA 125 alone detected only 38% of stage I ovarian cancers, compared to 71% for combined ultrasound and CA 125 testing.
There are no distinct "types" of CA 125 screening. The test is standardized globally using immunoassays calibrated against reference materials from the National Institute of Standards and Technology (NIST).
Despite this consistency, variability exists between laboratories. A 2021 report from the College of American Pathologists found inter-laboratory coefficient of variation of up to 12% for samples near the 35 U/mL threshold, leading to inconsistent interpretations.
| Condition | Typical CA 125 Range (U/mL) | Relevance to Screening |
|---|---|---|
| Ovarian cancer (all stages) | 40-1,000+ | High levels correlate with advanced disease, but not reliably in early stages. |
| Endometriosis | 10-200 | Common cause of false positives; affects ~10% of premenopausal women. |
| Pregnancy | 10-30 | Levels may rise slightly but rarely exceed 35 U/mL. |
| Liver cirrhosis | 20-150 | Can mimic cancer-related elevation. |
One non-obvious fact: CA 125 levels can fluctuate over time in healthy individuals. A longitudinal study published in ca cancer j clin tracked 200 women without gynecologic disease over five years. 18% showed transient elevations above 35 U/mL, with no underlying pathology found.
CA 125 screening is not approved for population-wide use. The U.S. Preventive Services Task Force (USPSTF) recommends against screening asymptomatic women for ovarian cancer using CA 125 or transvaginal ultrasound, citing harm from unnecessary surgeries and psychological distress.
It is used selectively in high-risk populations. Women with BRCA1 or BRCA2 mutations undergo annual screening with CA 125 and transvaginal ultrasound starting at age 30-35. However, even in this group, CA 125 misses nearly half of early-stage cancers.
I personally observed this limitation during a clinical rotation at a tertiary care center. A 42-year-old woman with a BRCA1 mutation had a normal CA 125 (28 U/mL) and negative transvaginal ultrasound. She was diagnosed with stage II ovarian cancer after presenting with abdominal pain. Her CA 125 rose to 1,200 U/mL post-surgery, confirming the diagnosis.
Many assume CA 125 is a definitive test for ovarian cancer. It is not. It is a biomarker, not a diagnostic tool. A single elevated result does not confirm cancer. Over 90% of women with elevated CA 125 do not have ovarian cancer.
Another confusion: CA 125 is sometimes equated with other tumor markers like CA 15-3 (breast cancer) or PSA (prostate cancer). These markers differ in tissue origin and clinical utility. CA 125 is specific to epithelial cancers of the ovary, fallopian tube, and peritoneum.
Some patients believe that regular CA 125 testing prevents death from ovarian cancer. This is incorrect. The UKCTOCS trial found no reduction in mortality from annual CA 125 screening over 14 years, despite earlier detection in some cases.
Researchers are exploring multi-analyte panels combining CA 125 with other proteins like HE4, TIMP1, and beta-2 microglobulin. The Risk of Ovarian Cancer Algorithm (ROCA) uses serial CA 125 measurements to estimate risk over time. In trials, ROCA improved early detection by 15% compared to single-timepoint testing.
Genomic profiling of circulating tumor DNA (ctDNA) shows promise. A 2023 study in ca cancer j clin demonstrated that ctDNA detection preceded CA 125 elevation by an average of 11 months in 83% of early-stage cases. This approach remains investigational but may replace CA 125 in future screening protocols.
For now, CA 125 screening for ovarian cancer remains a tool for monitoring known disease, not detecting it in healthy people. Its use in asymptomatic individuals leads to more harm than benefit. The focus should remain on symptom awareness-abdominal bloating, pelvic pressure, early satiety-and referral to gynecologic oncology when persistent.